Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Pharmacological PCO-prophylaxis using EGFR-inhibitor Gefitinib soaked IOLs as a drug carrier

Search Title by author or title

Session Details

Session Title: Posterior Capsule Opacification

Session Date/Time: Sunday 11/09/2016 | 08:30-10:00

Paper Time: 08:30

Venue: Hall C2

First Author: : N.Piravej GERMANY

Co Author(s): :    A. Kueres   C. Wertheimer   A. Wolf   C. Priglinger   S. Priglinger   K. Eibl-Lindner     

Abstract Details


A common complication after cataract surgery is posterior capsule opacification (PCO). EGF-Receptor selective inhibitor Gefitinib has been proven to mitigate the cellular basis of PCO in vitro and in an ex-vivo human capsular bag model. Yet there is no proper possibility to apply Gefitinib directly to the lens capsule. This study examines Gefitinib-presoaked intraocular lenses (IOL) as a drug carrier for PCO prophylaxis.


University Eye Hospital, Ludwig-Maximilians-University, Munich, Germany.


Gefitinib soaked IOLs were examined in an in-vitro anterior segment model as previously described by Gotoh et al. This in vitro anterior segment model imitates the in vivo human capsular bag situation, whereas cell proliferation and migration under the IOL can be observed and measured. Furthermore development of PCO was observed in a human capsular bag model in 24 eyes of 12 donors. Methods for securing human capsular bags were performed analogously to modern cataract surgery and were approved by the local ethics committee.


Compared to unsoaked control IOLs, Gefitinib modified IOLs were able to reduce PCO development significantly in both the Gotoh anterior segment model (p<0.05) and the human capsular bag model in vitro (p<0.05).


In the foreseeable future pharmacologically modified IOLs could reduce development of PCO and are therefore an encouraging attempt to improve efficacy of cataract surgery.

Financial Disclosure:


Back to previous